retatrutide phase 2 trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Phase 2 trial results demonstrate

GIPRs have been localized to human pancreatic -cells, and intravenous GIP infusion activates GIPR and intracellular signaling in pancreatic -cells, augmenting glucagonotropic effects in hypoglycemic conditions in humans (130)

Quality verification beyond vendor claims Researchers can implement additional verification steps beyond accepting vendor documentation

A combination of resistance training at least two to three times per week and protein intake of 1.2 to 1.6 g/kg per day has been shown to preserve and even increase lean mass during caloric restriction

Risk ratios (RR) for MACE estimates according to direct (DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors against placebo) and indirect (DPP-4 inhibitors vs GLP-1RA or SGLT-2 inhibitors, and GLP-1RA vs SGLT-2 inhibitors) comparisons

Shot day (and the day after): soft, low-fat, small plates

This necessitates careful monitoring and likely medication adjustment